FDA issues handful of new PDUFA dates

With the government shutdown resolved, FDA has accepted a handful of applications for review, according to company announcements early this week.

FDA granted Priority Review to two applications from Genentech Inc. for entrectinib and polatuzumab vedotin.

Entrectinib, an inhibitor of ROS1, TrkA, TrkB, TrkC

Read the full 436 word article

How to gain access

Continue reading with a
two-week free trial.